Cardiac biomarkers, particularly BNP, can be part of an effective screening strategy for anthracycline-related cardiotoxicity.
In this study, LVEF did not appear to be adequate for the detection of cardiotoxicity.
BNP may allow us to direct cardioprotective therapy. More analysis with high-sensitivity troponin is needed.